Make Versus Buy: Evaluating Your Aseptic Fill/Finish Manufacturing Strategy

Every biopharma company is eventually faced with the “make versus buy” decision – should they fill/finish their drug product in-house or outsource? Complicating things further, a third option also exists to outsource a portion while retaining some internal capabilities. For most companies, the choice to make or buy is not straightforward. Argonaut frequently works with clients while they evaluate their manufacturing needs, and we have assembled a list of common decision points for make versus buy in aseptic fill/finish. End the internal debate over how to fill and finish your drug product by using the evaluation criteria below.